Lorbrena (lorlatinib)

pCPA File Number: 21811

Negotiation Status:

Concluded without agreement

Indication(s):

Non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy) or metastatic, monotherapy for first-line treatment of adult patients

Sponsor/Manufacturer:

Pfizer Canada ULC

CDA-AMC Project Number:

PC0249-000

pCPA Engagement Letter Issued:

2022-06-08

Negotiation Process Concluded:

2022-08-26